Lgals1 Protein — Galectin 1 is a protein involved in neurodegenerative disease processes. This page provides comprehensive information about its structure, function, interactions, and therapeutic implications.
Galectin-1 (LGALS1) is a member of the galectin family of carbohydrate-binding proteins that recognize β-galactoside moieties. Unlike classical secreted proteins, galectin-1 lacks a signal peptide and is released through a non-classical pathway. This protein plays critical roles in immune regulation, neuronal development, and has emerged as an important modulator of neuroinflammation and neurodegenerative disease pathogenesis.
Galectin-1 has a distinctive structure:
The protein forms a β-sandwich structure with the carbohydrate-binding site in a shallow groove.
Galectin-1 shows dynamic expression:
| Cell Type | Expression Level |
|---|---|
| Neurons | High (specific subtypes) |
| Astrocytes | High |
| Microglia | Moderate |
| Schwann Cells | High |
| Immune Cells | Variable (activation-dependent) |
In the nervous system, galectin-1 is upregulated during development, injury, and in disease states.
Galectin-1 binds:
Galectin-1-targeting strategies:
| Model | Findings |
|---|---|
| LGALS1 Knockout | Enhanced T-cell proliferation, altered immunity |
| Transgenic LGALS1 | Neuroprotection in stroke models |
| EAE (MS model) | Reduced disease severity |
The study of Lgals1 Protein — Galectin 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Dumic J, et al. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616-635.
[2] Liu FT, et al. Galectins: structure, function and therapeutic potential. Immunol Rev. 2009;230(1):1-21.
[3] Yip W, et al. Galectin-3 in neurodegenerative diseases. J Neurochem. 2021;157(4):1055-1072.